Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Anderson

Showing results (231-240 of 235) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 235 results.
Nature Communications|December 5, 2015
MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumoursElizabeth J Perlman, Samantha Gadd, Stefan T Arold, et al.
Faraday Discussions|June 22, 2016
Bridging model and real catalysts: general discussionCharles Campbell, Michael Bowker, Michail Stamatakis, et al.
Faraday Discussions|June 22, 2016
Application of novel catalysts: general discussionAmy L Miller, Michael Bowker, Andrés García-Trenco, et al.
Brain : a Journal of Neurology|May 21, 2013
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulationSusan J Hayflick, Michael C Kruer, Allison Gregory, et al.
The Lancet. Oncology|July 24, 2020
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trialAaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al.
Pageof 24

Showing results (231-240 of 235) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 235 results.
Nature Communications|December 5, 2015
MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumoursElizabeth J Perlman, Samantha Gadd, Stefan T Arold, et al.
Faraday Discussions|June 22, 2016
Bridging model and real catalysts: general discussionCharles Campbell, Michael Bowker, Michail Stamatakis, et al.
Faraday Discussions|June 22, 2016
Application of novel catalysts: general discussionAmy L Miller, Michael Bowker, Andrés García-Trenco, et al.
Brain : a Journal of Neurology|May 21, 2013
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulationSusan J Hayflick, Michael C Kruer, Allison Gregory, et al.
The Lancet. Oncology|July 24, 2020
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trialAaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al.
Pageof 24